Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B.
The aim of this study was to evaluate the effect of interferon-alpha therapy on serum and liver HBV DNA in 20 patients with chronic hepatitis B and to correlate the presence or absence of HBV DNA with the clinical response. There were 11 responders and all lost HBV DNA from the serum. Ten of the 11 were followed for 36 months following IFN treatment and remained well with absence of HBeAg and HBV DNA from the serum and with normal ALT. Five also lost HBsAg. HBV DNA became undetectable in the liver of nine of 10 of these patients in whom liver tissue was available for study. HBV DNA persisted in the liver of seven of nine nonresponders and was not detected in two in spite of the presence of HBV DNA and HBeAg in the serum of these two patients. We conclude that IFN may induce long remissions in patients with chronic hepatitis B with loss of HBV DNA from the serum and that occasionally HBV DNA may persist in the liver of such patients.
Feinman
S V
SV
Department of Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada.
Berris
B
B
Sooknanan
R
R
Fernandes
B
B
Bojarski
S
S
D000328:Adult; D002908:Chronic Disease; D004279:DNA, Viral / Q000097:blood / Q000187:drug effects* / Q000378:metabolism*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000503:physiopathology; D006514:Hepatitis B Surface Antigens / Q000097:blood / Q000187:drug effects; D006513:Hepatitis B e Antigens / Q000097:blood / Q000187:drug effects; D006515:Hepatitis B virus / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha